CJC1295 no DAC + Ipamorelin
Research Applications

US Peptide Co

Mechanism of Action

This research blend combines CJC-1295 without DAC (a GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist). CJC-1295 NO DAC activates the GHRH receptor in the anterior pituitary, while Ipamorelin selectively binds to the GHS-R1a receptor. In research models, this combination allows for studying synergistic effects on growth hormone secretion through distinct but complementary signaling pathways, offering insights into complex neuroendocrine regulation.

Molecular Profile

- Components: CJC-1295 without DAC (3,368.9 Da) + Ipamorelin (711.9 Da)
- Sequence CJC-1295 NO DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH_2
- Sequence Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH_2

Research Applications

- Synergistic growth hormone pathway research
- Investigation of dual-mechanism hormone secretion
- Models examining GHRH and ghrelin receptor signaling
- Research on complementary neuroendocrine pathways

Laboratory Considerations

- Store lyophilized powder at -20°C
- Reconstituted solutions should be stored at 4°C
- Avoid repeated freeze-thaw cycles to maintain peptide integrity

References

1. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
3. Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577.
4. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416.